clinical trial

AB1563-HPR VITAMIN D LEVEL IS ASSOCIATED WITH PAIN AND PAIN CATASTROPHIZING IN PATIENTS WITH FIBROMYALGIA SYNDROME
S. Baglan Yentur, M. Ş. Elbasti

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2152; DOI: 10.1136/annrheumdis-2024-eular.4677
AB1673-PARE THE EXPERIENCE OF PAIN IN PEOPLE WITH RHEUMATOID ARTHRITIS – FINDINGS FROM A QUALITATIVE STUDY OF REMORA APP USERS’ EXPERIENCES
D. Dowding, S. Skyrme, Y. Masood, S. Van der Veer, K. Druce, D. Griffiths-Jones, W. Dixon, C. Sharp

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2213; DOI: 10.1136/annrheumdis-2024-eular.4324
AB1443 CONSISTENT SAFETY PROFILE OF SECUKINUMAB IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: UPDATE ON THE DATA FROM POOLED CLINICAL TRIALS
A. Deodhar, I. B. Mc‎ Innes, X. Baraliakos, A. B. Gottlieb, U. Kiltz, S. Schreiber, B. G. Sahoo, W. Bao, L. Pricop, C. Gaillez, V. Dong, P. J. Mease

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2078-2079; DOI: 10.1136/annrheumdis-2024-eular.5169
AB1469 PROSPECTIVE REGISTRATION IN RHEUMATOLOGY RANDOMIZED CONTROLLED TRIALS: WHERE WE ARE, WHY, AND HOW WE COULD GET BETTER
S. Capderou, D. Mongin, T. Agoritsas, D. S. Courvoisier, M. Iudici

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2099; DOI: 10.1136/annrheumdis-2024-eular.2815
AB1526 POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSES OF OBEXELIMAB IN HEALTHY VOLUNTEERS AND IN PATIENTS WITH RHEUMATOID ARTHRITIS OR IgG4-RELATED DISEASE
X. Wang, R. Kirk, H. Mu, T. Fischer

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2134; DOI: 10.1136/annrheumdis-2024-eular.3138
AB1548-HPR SYSTEMIC SCLEROSIS PATIENTS WITHOUT SEVERE ORGAN INVOLVEMENT HAVE A SIGNIFICANT REDUCED HEALTH STATE COMPARED TO THE GENERAL POPULATION
T. Garen, C. Nita, H. Fretheim, I. Barua, M. N. Carstens, H. Didriksen, V. K. Sarna, Ø. Midtvedt, Ø. Molberg, A. M. Hoffmann-Vold

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2145-2146; DOI: 10.1136/annrheumdis-2024-eular.5375
AB1562-HPR NEUTROPHIL TO LYMPHOCYTE RATIO AS A MARKER OF DISEASE ACTIVITY IN PATIENTS WITH KNEE OSTEOARTHRITIS
G. Qader

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2152; DOI: 10.1136/annrheumdis-2024-eular.4462
AB1328 IS THERE A NEED FOR ROUTINE IMAGING FOLLOW-UP IN PATIENTS WITH TAKAYASU ARTERITIS?
F. Yildirim, C. Bes, M. E. Kutu, S. Celik, F. Tastekin, G. Keser, T. Ocak, E. Dalkilic, Y. Pehlivan, H. Kocaayan, S. Akar, S. Isik, A. Omma, S. San, A. Yazici, A. Cefle, G. Kenar, F. Onen, A. Avcu, F. Alibaz- Oner, H. Direskeneli, B. C. Uludogan, N. S. Yasar Bilge, N. A. Kanitez

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2013-2014; DOI: 10.1136/annrheumdis-2024-eular.5892
AB1374 DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS
B. Strober, H. Sofen, S. Imafuku, C. Paul, M. Gooderham, L. Spelman, S. J. Seo, T. Passeron, R. M. Kisa, V. Berger, E. Vritzali, K. Hoyt, M. J. Colombo, S. Banerjee, M. Augustin, L. Stein Gold, A. Alexis, D. Thaçi, A. Blauvelt, M. Lebwohl

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2039-2040; DOI: 10.1136/annrheumdis-2024-eular.245
AB1381 GUSELKUMAB AND GOLIMUMAB COMBINATION INDUCTION THERAPY IN ULCERATIVE COLITIS RESULTS IN EARLY LOCAL TISSUE HEALING THAT IS SUSTAINED THROUGH GUSELKUMAB MAINTENANCE THERAPY
D. Richards, M. Vetter, M. Germinaro, B. Verstockt, R. Atreya, J. Panes, B. E. Sands, B. Feagan, B. Mcrae, D. Cua, P. Branigan, T. C. Freeman

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2043-2044; DOI: 10.1136/annrheumdis-2024-eular.2868

Main menu

clinical trial

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

clinical trial

Pages